Star Metro - Microbix Updates Investor Presentation on its Website

MISSISSAUGA, ON / ACCESS Newswire / January 9, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF) (Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it has updated the investor presentation on its corporate website in response to comments of staff of the Ontario Securities Commission (OSC & OSC Staff) in relation to its usage of earnings before interest, taxes, depreciation, and amortization (EBITDA), a measure of financial results not formally-defined by International Financial Reporting Standards (IFRS).

Specifically, over the course of a much broader OSC review of company continuous disclosure materials, it was identified that Microbix referred to EBITDA on two slides within its investor-oriented PowerPoint presentation. For those references, OSC Staff noted that Microbix did not provide the associated disclosures required by subsection 6.1(e) of National Instrument 52-112 (Non-GAAP and Other Financial Measures Disclosure) to explain the meaning of EBITDA to current or prospective investors with respect to:

• An explanation of the composition of the non-GAAP financial measure

• An explanation of how the measure provides useful information to an investor

• A quantitative reconciliation of the non-GAAP measure to the most directly comparable financial measure

OSC Staff identified the foregoing issue in the first of several letters to Microbix containing comments with respect to improving company disclosures and ensuring full compliance with the Ontario Securities Act ("Act") and the many OSC Staff Notices that provide issuers prescriptive guidance with respect to maintaining compliance with all rules and interpretations associated with the Act. In the course of updating all its continuous disclosure documents to fully incorporate and respect staff comments and guidance, Microbix updated the cited investor presentation for its fiscal Q3 2025 results without required additional disclosures related to EBITDA. Microbix's not responding to this particular OSC Staff comment resulted in this news release disclosure.

The revised investor presentation including additional non-GAAP financial measure disclosure can be viewed or downloaded from the investors section of the Microbix website at https://microbix.com or https://microbix.com/presentations

Microbix thanks OSC Staff for their constructive commentaries aimed to improve the precision of corporate disclosures by public companies and wishes everyone a happy New Year.

About Microbix Biosystems Inc.

Microbix Biosystems Inc. creates proprietary biological products for human health, with over 120 skilled employees and revenues of C$ 18.6 million in its last reported fiscal year (2025). It enables the worldwide commercialization of diagnostic assays by making a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) and reference materials (QUANTDx™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs or QUANTDx are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides IVDR-compliant CE marked products.

Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots, and reagents or media to support molecular diagnostic testing (e.g., its DxTM™ for patient-sample collection). Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada.

Forward-Looking Information

This news release includes "forward-looking information," as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, discussion of its investor presentation, its broader corporate disclosures, the OSC and its practices, the outlook for the business, risks associated with its financial results and stability, its current or future products, development projects such as those referenced herein, access to and sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity and timeliness of delivery), foreign currency and exchange rates, maintaining adequate working capital and raising further capital on acceptable terms or at all, and other similar statements concerning anticipated future events, conditions or results that are not historical facts. These statements reflect management's current estimates, beliefs, intentions, and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking information is inherently uncertain, and that actual performance may be affected by many material factors, some of which are beyond the Company's control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions, and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent the Company's judgement as of the date of this new release, and the Company is under no obligation to update or alter any forward-looking information except as required by applicable law.

Please visit www.microbix.com or www.sedarplus.ca for recent Microbix news and filings.

For further information, please contact Microbix at:

Copyright © 2025 Microbix Biosystems Inc.

Microbix®, DxTM™, Kinlytic®, QAPs™, and QUANTDx™ are trademarks of Microbix Biosystems Inc.

SOURCE: Microbix Biosystems Inc.

View the original press release on ACCESS Newswire

S.Morin--SMC